ASTH · Insider Trading
Astrana Health Inc. Common Stock
Every open-market purchase and sale reported by ASTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | John Vong | SVP - Accounting (PAO) | F | −556 | −$20.88K |
| 2026-10-08 | Brandon Sim | CEO and President | F | −9,889 | −$365.89K |
| 2026-10-08 | Thomas S. Lam | Director | F | −2,624 | −$97.09K |
| 2026-10-06 | Chandan Basho | COO and CFO | F | −2,092 | −$75.06K |
| 2026-09-17 | John Vong | SVP - Accounting (PAO) | F | −96 | −$3.68K |
| 2026-09-09 | Brandon Sim | CEO and President | F | −7,163 | −$275.56K |
| 2026-09-08 | Chandan Basho | COO and CFO | F | −1,790 | −$68.86K |
| 2026-09-01 | Mitchell W Kitayama | Director | D | −8,500 | −$315.26K |
| 2026-08-18 | David Schmidt | Director | MIXED | — | −$671.80K |
| 2026-08-11 | Glenn Sobotka | — | D | −11,793 | — |
| 2026-06-12 | Weili Dai | Director | A | +4,525 | — |
| 2026-06-12 | Matthew Mazdyasni | Director | A | +4,525 | — |
| 2026-06-12 | Mitchell W Kitayama | Director | A | +4,991 | — |
| 2026-06-12 | David Schmidt | Director | A | +4,525 | — |
| 2026-06-12 | John Chiang | Director | A | +4,525 | — |
| 2026-06-12 | Linda Dong | Director | A | +4,525 | — |
| 2026-05-18 | Chandan Basho | COO and CFO | F | −8,155 | −$312.01K |
| 2026-04-15 | Chandan Basho | COO and CFO | F | −3,870 | −$112.50K |
| 2026-04-08 | Kenneth T. Sim | Executive Chairman | A | +100,000 | — |
| 2026-04-08 | Brandon Sim | CEO and President | A | +201,056 | — |
| 2026-04-08 | Thomas S. Lam | Director | A | +41,667 | — |
| 2026-04-03 | Dinesh M. Kumar | Chief Medical Officer | MIXED | −22,680 | −$1.42M |
| 2026-04-03 | Chandan Basho | COO and CFO | F | −2,092 | −$52.40K |
| 2026-03-30 | Glenn Sobotka | Chief Accounting Officer | F | −662 | −$16.07K |
| 2026-03-09 | Dinesh M. Kumar | Chief Medical Officer | F | −1,697 | −$42.54K |
| 2026-03-09 | Chandan Basho | COO and CFO | F | −1,240 | −$31.09K |
| 2026-03-09 | Thomas S. Lam | Director | F | −9,266 | −$232.30K |
| 2026-02-03 | Brandon Sim | CEO and President | M | +21,334 | +$495.80K |
| 2026-01-27 | Dinesh M. Kumar | Chief Medical Officer | F | −10,759 | −$292.21K |
| 2026-01-15 | David Schmidt | Director | MIXED | +15,731 | +$25 |
| 2026-01-05 | Dinesh M. Kumar | Chief Medical Officer | F | −5,102 | −$126.58K |
| 2025-12-10 | Thomas S. Lam | Director | MIXED | +3,636 | −$44.51K |
| 2025-11-13 | Kenneth T. Sim | Executive Chairman | M | +29,502 | +$524.55K |
| 2025-11-12 | Matthew Mazdyasni | Director | M | +20,000 | +$364.00K |
| 2025-11-12 | Mitchell W Kitayama | Director | M | +12,000 | +$218.40K |
| 2025-11-05 | Linda Marsh | Director | MIXED | +8,967 | +$21 |
| 2025-10-06 | Chandan Basho | COO and CFO | F | −1,979 | −$54.96K |
| 2025-09-15 | Mitchell W Kitayama | Director | MIXED | −5,214 | −$253.86K |
| 2025-09-09 | Dinesh M. Kumar | Chief Medical Officer | F | −1,694 | −$50.31K |
| 2025-09-09 | Chandan Basho | COO and CFO | F | −1,694 | −$50.31K |
| 2025-09-03 | David Schmidt | Director | MIXED | — | −$191.20K |
| 2025-08-14 | John Chiang | Director | MIXED | +7,716 | +$25 |
| 2025-07-02 | Dinesh M. Kumar | Chief Medical Officer | F | −6,831 | −$171.18K |
| 2025-06-13 | David Schmidt | Director | A | +6,449 | — |
| 2025-06-13 | Matthew Mazdyasni | Director | A | +6,449 | — |
| 2025-06-13 | Weili Dai | Director | A | +6,449 | — |
| 2025-06-13 | John Chiang | Director | A | +6,449 | — |
| 2025-06-13 | Mitchell W Kitayama | Director | A | +6,449 | — |
| 2025-06-13 | Linda Marsh | Director | A | +6,449 | — |
| 2025-06-06 | Dinesh M. Kumar | Chief Medical Officer | F | −1,656 | −$41.50K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Kenneth T. Sim | Executive Chairman | 6,872,209 | $255.85M |
| Thomas S. Lam | Director | 6,595,835 | $245.56M |
| ALLIED PHYSICIANS OF CALIFORNIA, A PROFESSIONAL MEDICAL Corp | 10%+ Owner | 6,132,802 | $228.32M |
| Brandon Sim | CEO and President | 1,487,796 | $55.39M |
| Dinesh M. Kumar | Chief Medical Officer | 177,655 | $6.61M |
| Chandan Basho | COO and CFO | 155,728 | $5.80M |
| Linda Dong | Director | 97,133 | $3.62M |
| David Schmidt | Director | 56,019 | $2.09M |
| Matthew Mazdyasni | Director | 39,288 | $1.46M |
| John Chiang | Director | 35,373 | $1.32M |
| Mitchell W Kitayama | Director | 24,337 | $906.07K |
| John Vong | SVP - Accounting (PAO) | 21,774 | $810.65K |
| Weili Dai | Director | 18,188 | $677.14K |
| Glenn Sobotka | Chief Accounting Officer | 2,246 | $83.62K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASTH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.